Literature DB >> 21475015

Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience.

Sheung Tat Fan1, Chung Mau Lo, Ronnie T P Poon, Chun Yeung, Chi Leung Liu, Wai Key Yuen, Chi Ming Lam, Kelvin K C Ng, See Ching Chan.   

Abstract

OBJECTIVE: To investigate the trend of the posthepatectomy survival outcomes of hepatocellular carcinoma (HCC) patients by analysis of a prospective cohort of 1198 patients over a 20-year period.
BACKGROUND: The hospital mortality rate of hepatectomy for HCC has improved but the long-term survival rate remains unsatisfactory. We reported an improvement of survival results 10 years ago. It was not known whether there has been further improvement of results in recent years.
METHODS: The patients were categorized into two 10-year periods: period 1, before 1999 (group 1, n = 390) and period 2, after 1999 (group 2, n = 808). Patients in group 2 were managed according to a modified protocol and technique established in previous years.
RESULTS: The patients in group 2 were older and had a higher incidence of comorbid illness and cirrhosis. They had a lower hospital mortality rate (3.1% vs 6.2%, P = 0.012) and longer 5-year overall survival (54.8% vs 42.1%, P < 0.001) and disease-free survival rates (34.8% vs 24%, P = 0.0024). An improvement in the overall survival rate was observed in patients with cirrhosis, those undergoing major hepatectomy, and those with tumors of tumor-node-metastasis stages II, IIIA, and IVA. A significant increase in the survival rates was also seen in patients whose tumors were considered transplantable by the Milan criteria (72.5% vs 62.7%, P = 0.0237). Multivariate analysis showed a significantly more favorable patient survival for hepatectomy in period 2.
CONCLUSIONS: A continuous improvement of survival outcomes after hepatectomy for HCC was achieved in the past 20 years even in patients with advanced diseases. Hepatectomy remains the treatment of choice for resectable HCC in a predominantly hepatitis B virus-based Asian population.

Entities:  

Mesh:

Year:  2011        PMID: 21475015     DOI: 10.1097/SLA.0b013e3182111195

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  137 in total

1.  A preclinical study on the combination therapy of everolimus and transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Ariel Km Chow; Thomas Cc Yau; Lui Ng; Andrew Cy Chu; Wai-Lun Law; Ronnie Tp Poon; Roberta Wc Pang
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

Review 2.  Laparoscopic liver resection for hepatocellular carcinoma in patients with cirrhosis.

Authors:  Tan To Cheung; Chung Mau Lo
Journal:  Hepatobiliary Surg Nutr       Date:  2015-12       Impact factor: 7.293

Review 3.  Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Stacey M Stein; Hyun S Kim
Journal:  Liver Cancer       Date:  2019-01-16       Impact factor: 11.740

Review 4.  Surgical management of hepatocellular carcinoma.

Authors:  Tony Cy Pang; Vincent Wt Lam
Journal:  World J Hepatol       Date:  2015-02-27

5.  Outcomes of central bisectionectomy for hepatocellular carcinoma.

Authors:  Thomas K Gallagher; Albert C Y Chan; Ronnie T P Poon; Tan To Cheung; Kenneth S H Chok; See Ching Chan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-11-21       Impact factor: 3.647

6.  Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma.

Authors:  Brian K P Goh; Pierce K H Chow; Jin-Yao Teo; Jen-San Wong; Chung-Yip Chan; Peng-Chung Cheow; Alexander Y F Chung; London L P J Ooi
Journal:  J Gastrointest Surg       Date:  2014-05-23       Impact factor: 3.452

7.  Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?

Authors:  Theodoros Michelakos; Dimitrios Xourafas; Motaz Qadan; Rafael Pieretti-Vanmarcke; Lei Cai; Madhukar S Patel; Joel T Adler; Fermin Fontan; Usama Basit; Parsia A Vagefi; Nahel Elias; Kenneth K Tanabe; David Berger; Heidi Yeh; James F Markmann; David C Chang; Cristina R Ferrone
Journal:  J Gastrointest Surg       Date:  2018-09-14       Impact factor: 3.452

8.  Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system.

Authors:  Albert C Y Chan; Sheung Tat Fan; Ronnie T P Poon; Tan To Cheung; Kenneth S H Chok; See Ching Chan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-12-02       Impact factor: 3.647

Review 9.  How much ischemia can the liver tolerate during resection?

Authors:  Wouter G van Riel; Rowan F van Golen; Megan J Reiniers; Michal Heger; Thomas M van Gulik
Journal:  Hepatobiliary Surg Nutr       Date:  2016-02       Impact factor: 7.293

Review 10.  Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.

Authors:  René Fahrner; Felix Dondorf; Michael Ardelt; Yves Dittmar; Utz Settmacher; Falk Rauchfuß
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.